3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
20
Phase NA
14
Phase 3
10
Phase 1
8
Phase EARLY_PHASE1
4
Phase 1/2
4
Phase 4
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Head and Neck Neoplasms
32
Squamous Cell Carcinoma of Head and Neck
24
Nasopharyngeal Carcinoma
10
Mouth Neoplasms
10
Thyroid Neoplasms
9
Oropharyngeal Neoplasms
9
Laryngeal Neoplasms
8
Ovarian Neoplasms
5
Lung Neoplasms
5
Hypopharyngeal Neoplasms
5
Colorectal Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Melanoma
4
Carcinoma, Squamous Cell
4
Carcinoma
4
Thyroid Carcinoma, Anaplastic
3
Thyroid Cancer, Papillary
3
Recurrence
3
Neoplasms, Squamous Cell
3
Nasopharyngeal Neoplasms
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomatitis
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Parathyroid Neoplasms
2
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Laryngeal Diseases
×
Head & Neck
×
Clear all
NCT06788990
2026-06-02
FORTIFI-HN01
Bicara Therapeutics
Phase 2/3
Recruiting
650 enrolled